{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(24)00357-1","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Tranexamic acid not recommended for liver cancer surgery</h2>Tranexamic acid does not reduce bleeding and increases major complications in liver cancer surgery, according to new findings from the <span><span>HeLiX trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>. Paul Karanicolas and colleagues randomly assigned patients undergoing liver resection for cancer to receive either tranexamic acid (n=619) or matching placebo (n=626) beginning at induction of anaesthesia. The primary outcome—receipt of a red blood cell transfusion within 7 days of surgery—occurred in 101 (16%) patients in the tranexamic acid group</section></section><section><section><h2>Oral microbiome therapeutic for recurrent <em>C difficile</em></h2><span><span>CP101</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, an oral microbiome therapeutic, restores microbiome diversity and offers a safe effective treatment option for recurrent <em>C difficile</em> infections, according to a phase 2 trial. Jessica Allegretti and colleagues randomly assigned participants with recurrent <em>C difficile</em> to receive a single oral dose of either CP101 (n=102) or placebo (n=96) after standard-of-care antibiotics. At week 8, a significantly higher proportion of participants in the CP101 group achieved had not had <em>C difficile</em></section></section><section><section><h2>Liver transplantation for inoperative colorectal liver metastases</h2>Long-term survival is possible after liver transplant for colorectal liver metastases, according to the <span><span>TransMet trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>. René Adam and colleagues randomly assigned patients with permanently unresectable colorectal liver metastases to receive liver transplantation plus chemotherapy (n=47) or chemotherapy alone (n=47). The per-protocol population of patients who received the assigned treatment included 36 patients in liver transplantation plus chemotherapy group and 38 in the chemotherapy alone</section></section><section><section><h2><span><span>Palliative radiotherapy</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> for hepatic cancer</h2>Low-dose liver radiotherapy improves pain in patients receiving palliative care for hepatic cancer, a phase 3 trial suggests. Laura Dawson and colleagues randomly assigned patients with hepatocellular carcinoma or liver metastases, and a pain score of at least 4 out of 10 “at its worst in the past 24 hours” on the Brief Pain Inventory, to receive a single fraction of radiotherapy (8 Gy) plus best supportive care (n=33) or best supportive care alone (n=33). At median follow-up of 3·2 months,</section></section><section><section><h2>Tulisokibart for ulcerative colitis</h2>Tulisokibart—a TNF–like cytokine 1A (TL1A) monoclonal antibody—shows promise in patients with moderately to severely active ulcerative colitis, according to the <span><span>ARTEMIS-UC phase 2 trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>. Bruce Sands and colleagues enrolled patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis into two cohorts. Cohort 1 included patients regardless of their status on a genetic-based diagnostic test designed to identify those with an increased likelihood</section></section>","PeriodicalId":30,"journal":{"name":"Biomacromolecules","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomacromolecules","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(24)00357-1","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Section snippets
Tranexamic acid not recommended for liver cancer surgery
Tranexamic acid does not reduce bleeding and increases major complications in liver cancer surgery, according to new findings from the HeLiX trial. Paul Karanicolas and colleagues randomly assigned patients undergoing liver resection for cancer to receive either tranexamic acid (n=619) or matching placebo (n=626) beginning at induction of anaesthesia. The primary outcome—receipt of a red blood cell transfusion within 7 days of surgery—occurred in 101 (16%) patients in the tranexamic acid group
Oral microbiome therapeutic for recurrent C difficile
CP101, an oral microbiome therapeutic, restores microbiome diversity and offers a safe effective treatment option for recurrent C difficile infections, according to a phase 2 trial. Jessica Allegretti and colleagues randomly assigned participants with recurrent C difficile to receive a single oral dose of either CP101 (n=102) or placebo (n=96) after standard-of-care antibiotics. At week 8, a significantly higher proportion of participants in the CP101 group achieved had not had C difficile
Liver transplantation for inoperative colorectal liver metastases
Long-term survival is possible after liver transplant for colorectal liver metastases, according to the TransMet trial. René Adam and colleagues randomly assigned patients with permanently unresectable colorectal liver metastases to receive liver transplantation plus chemotherapy (n=47) or chemotherapy alone (n=47). The per-protocol population of patients who received the assigned treatment included 36 patients in liver transplantation plus chemotherapy group and 38 in the chemotherapy alone
Palliative radiotherapy for hepatic cancer
Low-dose liver radiotherapy improves pain in patients receiving palliative care for hepatic cancer, a phase 3 trial suggests. Laura Dawson and colleagues randomly assigned patients with hepatocellular carcinoma or liver metastases, and a pain score of at least 4 out of 10 “at its worst in the past 24 hours” on the Brief Pain Inventory, to receive a single fraction of radiotherapy (8 Gy) plus best supportive care (n=33) or best supportive care alone (n=33). At median follow-up of 3·2 months,
Tulisokibart for ulcerative colitis
Tulisokibart—a TNF–like cytokine 1A (TL1A) monoclonal antibody—shows promise in patients with moderately to severely active ulcerative colitis, according to the ARTEMIS-UC phase 2 trial. Bruce Sands and colleagues enrolled patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis into two cohorts. Cohort 1 included patients regardless of their status on a genetic-based diagnostic test designed to identify those with an increased likelihood
期刊介绍:
Biomacromolecules is a leading forum for the dissemination of cutting-edge research at the interface of polymer science and biology. Submissions to Biomacromolecules should contain strong elements of innovation in terms of macromolecular design, synthesis and characterization, or in the application of polymer materials to biology and medicine.
Topics covered by Biomacromolecules include, but are not exclusively limited to: sustainable polymers, polymers based on natural and renewable resources, degradable polymers, polymer conjugates, polymeric drugs, polymers in biocatalysis, biomacromolecular assembly, biomimetic polymers, polymer-biomineral hybrids, biomimetic-polymer processing, polymer recycling, bioactive polymer surfaces, original polymer design for biomedical applications such as immunotherapy, drug delivery, gene delivery, antimicrobial applications, diagnostic imaging and biosensing, polymers in tissue engineering and regenerative medicine, polymeric scaffolds and hydrogels for cell culture and delivery.